Current information on the safety of medicinal products

The U.S. Food and Drug Administration (FDA) requires changes to be made to the package inserts of benzodiazepines

25.09.2020 1360

Управління по контролю якості харчових продуктів та лікарських засобів США вимагає внести зміни до інструкції для медичного застосування класу препаратів…

Analysis of spontaneous reports of adverse reactions associated with the use of medicinal products in the treatment of COVID-19 that were received by the WHO Global Database of Individual Case Safety Reports – VigiBase, interim results (report date 26.08.2020)

09.09.2020 1280

The Uppsala Monitoring Centre (UMC) provides a 11 global report on cases of adverse reactions (hereinafter – ARs) following the use of medicinal products (hereinafter…

FDA approves changes for medicinal products containing hydrochlorothiazide regarding a warning about a slight risk of non-melanoma skin cancer

21.08.2020 1329

Управління по контролю якості харчових продуктів та лікарських засобів США FDA схвалює зміни для лікарських засобів, які містять hydrochlorothiazide щодо…

Analysis of spontaneous reports of adverse reactions associated with the use of medicinal products in the treatment of COVID-19 that were received by the WHO Global Database of Individual Case Safety Reports – VigiBase, interim results (report date 12.08.2020)

20.08.2020 1158

The Uppsala Monitoring Centre (UMC) provides a 10 global report on cases of adverse reactions (hereinafter – ARs) following the use of medicinal products (hereinafter…

Vaccination against hepatitis B. Refutation of high-profile statements by the mass media of the city of Lutsk.

18.08.2020 1914

Нещодавно у засобах масових інформацій м. Луцька було оприлюднено інформацію стосовно важких наслідків застосування вакцини проти гепатиту В у новонародженої…

Analysis of spontaneous reports of adverse reactions associated with the use of medicinal products in the treatment of COVID-19 that were received by the WHO Global Database of Individual Case Safety Reports – VigiBase, interim results (report date 22.07.2020)

07.08.2020 1279

The Uppsala Monitoring Centre (UMC) provides a 9 global report on cases of adverse reactions (hereinafter – ARs) following the use of medicinal products (hereinafter…

Analysis of reports from applicants on cases of adverse reactions associated with the use of medicinal products in the treatment of COVID19 and received by the Center during July 2020

06.08.2020 1313

Аналіз повідомлень від заявників про випадки побічних реакцій, що пов’язані із застосуванням лікарських засобів при лікуванні COVID19, та надійшли до…

FDA recommends that healthcare professionals discuss the use of naloxone with patients when prescribing opioid pain medicines or when using medicines for the treatment of opioid use disorders

30.07.2020 1932

Щоб знизити ризик смерті від передозування опіоїдів, американська агенція з контролю за продуктами харчування та лікарськими засобами (FDA) приймає наступні…

FDA. Review of safety data on medicinal products containing hydroxychloroquine and chloroquine during treatment of COVID-19

10.07.2020 2226

28 березня 2020 року Управління з контролю за харчовими продуктами та лікарськими засобами США (FDA) дозволила екстрене використання гідроксихлорохіну та…

Analysis of spontaneous reports of adverse reactions associated with the use of medicinal products in the treatment of COVID-19 and submitted to VigiBase: interim results (report date 01.07.2020)

10.07.2020 1176

Проміжний звіт Центру моніторингу Уппсала (UMC) за даними VigiBase станом на 01.07.2020 про спонтанні повідомлення щодо побічних реакцій при застосуванні лікарських засобів для лікування COVID-19. Містить узагальнену статистику, демографічні дані пацієнтів, спектр побічних реакцій та інформацію про летальні випадки. складено автоматично

The U.S. Food and Drug Administration (FDA) requires changes to be made to the package inserts of benzodiazepines

Analysis of spontaneous reports of adverse reactions associated with the use of medicinal products in the treatment of COVID-19 that were received by the WHO Global Database of Individual Case Safety Reports – VigiBase, interim results (report date 26.08.2020)

FDA approves changes for medicinal products containing hydrochlorothiazide regarding a warning about a slight risk of non-melanoma skin cancer

Analysis of spontaneous reports of adverse reactions associated with the use of medicinal products in the treatment of COVID-19 that were received by the WHO Global Database of Individual Case Safety Reports – VigiBase, interim results (report date 12.08.2020)

Vaccination against hepatitis B. Refutation of high-profile statements by the mass media of the city of Lutsk.

Analysis of spontaneous reports of adverse reactions associated with the use of medicinal products in the treatment of COVID-19 that were received by the WHO Global Database of Individual Case Safety Reports – VigiBase, interim results (report date 22.07.2020)

Analysis of reports from applicants on cases of adverse reactions associated with the use of medicinal products in the treatment of COVID19 and received by the Center during July 2020

FDA recommends that healthcare professionals discuss the use of naloxone with patients when prescribing opioid pain medicines or when using medicines for the treatment of opioid use disorders

FDA. Review of safety data on medicinal products containing hydroxychloroquine and chloroquine during treatment of COVID-19

Analysis of spontaneous reports of adverse reactions associated with the use of medicinal products in the treatment of COVID-19 and submitted to VigiBase: interim results (report date 01.07.2020)

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration